Moreover, sorafenib can also affect tumor angiogenesis through VEGFR and PDGFR inhibition, and different studies have shown that co-treatment of EGFR-TKIs with antiangiogenic drugs can improve progression-free survival of NSCLC patients76–78. This evidence concerns the gene EGFR and non-small cell lung carcinoma.